<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An update from IN8bio ( (INAB) ) is now available. IN8bio, Inc., a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers for cancer and autoimmune diseases, reported first quarter 2026 results and shareholder voting outcomes on May 7, 2026. The company’s portfolio includes the INB-600 engager platform, INB-100 for high-risk leukemias and INB-200/400 for newly diagnosed glioblastoma, reflecting a strategic focus on cell-based therapies for severe, underserved indications. At its May 7, 2026 annual meeting, shareholders elected two Class II directors through 2029, ratified CohnReznick LLP as auditor for 2026, and approved the 2026 equity incentive plan, reinforcing governance continuity and funding for talent retention. Operationally, IN8bio highlighted preclinical progress for INB-619, updated Phase 1/2 glioblastoma data showing about 97% improvement in median progression-free survival versus standard-of-care as of December 31, 2025, and a strengthened cash position of $21.9 million alongside a narrower quarterly net loss, underscoring both clinical momentum and improved financial flexibility. The company is using its GBM data, which also showed rising median overall survival and an encouraging safety profile with no dose-limiting toxicities or major neurotoxic events, to engage regulators on potential pathways for its glioblastoma program. A series of upcoming scientific presentations, including at ASCO, ISCT and ASGCT in May and June 2026, together with an R&amp;D Day in New York City on May 21, 2026, are intended to raise IN8bio’s profile among clinicians and investors as it advances IND-enabling work for INB-619 and approaches multiple late-2026 clinical and regulatory milestones. The most recent analyst rating on (INAB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page. Spark’s Take on INAB Stock According to Spark, TipRanks’ AI Analyst, INAB is a Neutral. The score is held down primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow), with technicals also reflecting a continuing downtrend. Modest leverage and a constructive leadership move provide some support, but limited valuation visibility and ongoing funding risk keep the overall score low. To see Spark’s full report on INAB stock, click here. More about IN8bio IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta (γδ) T cell therapies and γδ T cell engagers to address unmet medical needs in oncology and autoimmune diseases. Its pipeline centers on the INB-600 γδ T cell engager platform, the INB-100 allogeneic γδ T cell therapy for high-risk leukemias undergoing haploidentical stem cell transplant, and the INB-200/400 autologous genetically modified γδ T cell programs for newly diagnosed glioblastoma. Average Trading Volume: 60,137 Technical Sentiment Signal: Sell Current Market Cap: $15.56M For an in-depth examination of INAB stock, go to TipRanks’ Overview page.</div>

INAB

LABU

IN8bio, Inc. reported its Q1 2026 results and shareholder voting outcomes on May 7, 2026. The company, focused on γδ T cell therapies for cancer, highlighted preclinical progress and a strengthened cash position of $21.9 million. Shareholders elected two directors, ratified the auditor, and approved the equity incentive plan. Analyst ratings for INAB stock are mixed, with a Buy rating and a $5.00 price target, while Spark's AI Analyst rates it as Neutral due to weak financial performance and ongoing losses. Upcoming scientific presentations aim to enhance the company's visibility.

IN8bio Reports Q1 2026 Results and Shareholder Votes